Conformis (CFMS) Stock Price, News & Analysis

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CFMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CFMS, but not buy additional shares or sell existing shares.
View CFMS analyst ratings or view top-rated stocks.

Conformis, Inc. (NASDAQ:CFMS) posted its quarterly earnings results on Wednesday, November, 3rd. The medical instruments supplier reported ($1.75) EPS for the quarter, meeting analysts' consensus estimates of ($1.75). The medical instruments supplier earned $14.25 million during the quarter, compared to the consensus estimate of $14.08 million. Conformis had a negative trailing twelve-month return on equity of 86.46% and a negative net margin of 72.72%. During the same period in the previous year, the firm posted ($2.25) EPS.

Conformis's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

15 employees have rated Conformis Chief Executive Officer Mark Augusti on Glassdoor.com. Mark Augusti has an approval rating of 55% among the company's employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).

Conformis (CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.